WallStreetZenWallStreetZen

NASDAQ: CING
Cingulate Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their CING stock forecasts and price targets.

Forecast return on equity

Is CING forecast to generate an efficient return?
Company
-1,692.05%
Industry
25.3%
Market
13.14%
CING's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CING forecast to generate an efficient return on assets?
Company
-990.41%
Industry
4.64%
CING is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CING earnings per share forecast

What is CING's earnings per share in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$9.00

CING vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CING$0.34N/AN/A
ATNF$2.14N/AN/A
VRPX$1.70$3.00+76.47%Strong Buy
VRAX$1.17N/AN/A
WINT$3.61N/AN/A

Cingulate Stock Forecast FAQ

What is CING's earnings growth forecast for 2024-2024?

(NASDAQ: CING) Cingulate's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.

Cingulate's earnings in 2024 is -$22,502,537.

In 2024, CING is forecast to generate -$54,418,311 in earnings, with the lowest earnings forecast at -$54,418,311 and the highest earnings forecast at -$54,418,311.

If you're new to stock investing, here's how to buy Cingulate stock.

What is CING's forecast return on equity (ROE) for 2024-2024?

(NASDAQ: CING) forecast ROE is -1,692.05%, which is considered weak.

What is CING's Earnings Per Share (EPS) forecast for 2024-2024?

(NASDAQ: CING) Cingulate's current Earnings Per Share (EPS) is -$20.81. In 2024, CING's EPS is forecast to hit -$9.00 (min: -$9.00, max: -$9.00).

What is CING's forecast return on assets (ROA) for 2024-2024?

(NASDAQ: CING) forecast ROA is -990.41%, which is lower than the forecast US Biotechnology industry average of 4.64%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.